Probing into the nexus of medical progress, ageing, and health expenditure

Michael Kuhn
Economic Frontiers Program
International Institute for Applied Systems Analysis

10th DHE Anniversary Symposium, Vienna, 25 September 2023
The nexus

Life expectancy, 1950 to 2021

Source: UN WorldPop (2022); Zietzmann et al. (2019); Riley (2005).
Note: Shown is the period life expectancy. This is the average number of years a newborn would live if age-specific mortality rates in the current year were to stay the same throughout its life.

Government health expenditure as a share of GDP, 1960 to 2021

This metric captures spending on government funded health care systems and social health insurance, as well as compulsory health insurance.

Source: Our World in Data based on Lindert (1984); OECD (2019); OECD Stat.
Note: Health spending includes final consumption of health care goods and services (i.e. current health expenditure). This excludes spending on capital investments.

OurWorldInData.org/health-care - CC BY
The nexus

Cutler, Lichtenberg
Buxbaum et al. (2020)
Fonseca et al. (2021)

Newhouse (1992)
Fang et al. (2007)
Breyer et al. (2015)
French et al. (2017)
The nexus


The nexus

Cutler, Lichtenberg
Buxbaum et al. (2020)
Fonseca et al. (2021)

Acemoglu &
Linn (2004)
Wong et al.
(2012)

Newhouse (1992)
Finkelstein (2007)
Clemens & Olsen
(2021)

Fang et al. (2007)
Breyer et al. (2015)
French et al. (2017)

Lichtenberg (2004)
Martin et al. (2008)
Baltagi et al. (2012)

\[ \text{Health Share of R&D (percent)} \]

Copyright © 2016 The University of Chicago.

Source: UN WPP (2022); Zibelman et al. (2015); Riley (2005).
Note: Shown is the 'period life expectancy'. This is the average number of years a newborn would live if age-specific mortality rates in the current year were to stay the same throughout its life.

Note: Health spending includes final consumption of health care goods and services (i.e. current health expenditure). This excludes spending on capital investments.

Our World in Data - CC BY
Cutting the nexus: The MEDPRO project

- Accept mutual causality (complementarity) along the nexus but apply theoretical yet calibrated models to understand some of the linkages and employ counterfactual analysis to trace out...

- ... (a) the mechanisms and incentives behind medical progress and their role as policy levers (b) the impact on longevity, health spending, economic performance but ultimately welfare!

- Settings:
  
  Impact of cardiac revolution and role of medical diffusion (Frankovic et al., J Macro Econ, 2020)

  Impact of health insurance expansion on medical progress and outcomes (Frankovic and Kuhn, JHE, 2023)

  Medical progress and the longevity gap (Frankovic and Kuhn, J Econ Ageing, 2019)

  Impact of medical progress in a public health care system with congestion (Kelly and Kuhn, J Macro Econ, 2022)
Model features

- General equilibrium model of overlapping generations of households with realistic demography (i.e. survival rates and, thus, age structure).
- Individuals consume, save and utilize health care over their life-cycle.
- **Health care lowers mortality** subject to decreasing returns but enhanced by medical progress. Contribution of health care to mortality change calibrated to 30%-50% (following e.g. Ford et al. 2006, NEJM).
- Final goods and health care sector produce with capital and labour (calibrated to realistic factor shares and labour productivity growth).
- Models calibrated to **US economy and health care** (data!) broadly 1960-2010.
- Medical progress raises impact of health care on mortality (**product rather than process innovation**) which is in line with increasing nominal prices of treatments but declining quality-adjusted prices!
Impact of cardiac revolution 1980-2005

- Calibrated to **cardiac revolution between 1980-2005**; 32.5% of life expectancy to be explained by medical progress & health care utilization

- **Diffusion lag 8.9 years** (Skinner & Staiger, 2015: 5-10 years)

- Calibrated benchmark
- No medical progress
- Instantaneous diffusion
Impact of cardiac revolution: welfare

- **Compensating variation for medical progress:** % life cycle consumption that individuals in a world without medical progress would need to receive to attain same utility as in the benchmark.

- **Compensating variation for perfect diffusion:** % life cycle consumption that individuals in a world with perfect diffusion would need to give up to receive same utility as in the benchmark.
Impact of health insurance expansion 1965-2005

- **Health insurance** modelled as pure subsidy (no value to insurance per se)

- **3rd sector: Medical R&D produced with capital and labour.** Quality competition in health care sector => producer surplus converted into purchases of medical technology.

- Calibrated benchmark
- No insurance expansion
Health insurance expansion: moral hazard

- Insurance moral hazard: pure subsidy => excessive consumption
- Health expenditure growth without sizeable increase in life expectancy (flat-of-the-curve medicine)

- Calibrated benchmark
- No insurance expansion
- Insurance expansion without medical progress (moral hazard)
Health insurance expansion: Welfare impacts

- Gains from **medical progress overcompensate losses from moral hazard** for all cohorts
- Early cohorts stand to gain little from medical progress (too late) but actually gain from moral hazard (access to health care in old age)
- **Trading two intergenerational externalities:** Excessive consumption by old imposes moral hazard burden on young but advances medical progress that is benefitting the young!
- Net welfare gains **contingent on sufficient income growth** (a la Hall and Jones, 2007; Jones 2016).
Medical progress and the SES mortality gap

- Chetty et al. (JAMA, 2016) and many others: Large (and growing) longevity gap by income (and other SES indicators)
- Introduce two skill/income groups into our model to study role of medical progress. The skilled...
  
  ...earn higher income (in 1960) and increasingly so due to skill-biased technical progress
  ...have an advantage in the timely access to (and effective use of) state-of-the art health care
  ...have lower co-insurance
  ...may be less vulnerable to medical price inflation
Medical progress: Channels

- Decomposition: Compare **benchmark** with all channels against **counterfactuals in which individual channels are turned off**: compare resulting changes in longevity gap

- Benchmark = all disadvantages active

- Counterfactuals I-III = eliminate one of the disadvantages each (note: medical price inflation does not create disadvantage for the unskilled)

**Comparing Benchmark and Counterfactuals (CFs) to identify contribution of biases.**

<table>
<thead>
<tr>
<th>Longevity gap</th>
<th>in 2015</th>
<th>Increase 1960–2015</th>
<th>due to bias</th>
<th>share of benchmark increase explained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benchmark</td>
<td>4.5 years</td>
<td>2.1 years</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CF I: no skill-bias in earnings</td>
<td>4.1 years</td>
<td>1.7 years</td>
<td>0.4 years</td>
<td>19%</td>
</tr>
<tr>
<td>CF II: no skill-bias in med. eff.</td>
<td>3.3 years</td>
<td>0.9 years</td>
<td>1.2 years</td>
<td>57%</td>
</tr>
<tr>
<td>CF III: no skill-bias in insurance</td>
<td>4.4 years</td>
<td>2.0 years</td>
<td>0.1 years</td>
<td>5%</td>
</tr>
<tr>
<td>Sum CF I-III</td>
<td></td>
<td></td>
<td>1.7 years</td>
<td>81%</td>
</tr>
<tr>
<td>CF V: CF I-III combined</td>
<td>2.9 years</td>
<td>0.5 years</td>
<td>–</td>
<td>24%</td>
</tr>
</tbody>
</table>

- Counterfactual V: **Initial income inequality** translates into **differences in the demand for health care**. These are **leveraged** in their impact on longevity by **medical progress**!
Summary and Outlook

- Despite greater health care spending, there are **sizeable welfare gains to medical progress** – assuming concomitant productivity/income growth! Specific dynamics (e.g. diffusion) matter.
- Health insurance: benefits from **induced medical progress overcompensate moral hazard**
- Starting from a situation in which direct subsidization of medical R&D (with future gains!) may be not politically favoured by current generations, **health insurance** (favouring the current old) may provide a **second-best**.
- Medical progress has strong potential to **boost the longevity gap**
- **Results carry over to a public health care system with congestion** (e.g. waiting): potential gains from medical progress cannot fully materialize if demand increase translates into congestion/waiting. To make medical progress effective, capacity would need to be increased.

Outlook

- Micro-processes and new types of medical R&D
- Medical innovation impacts in the very long-run (empirical study)
- Further work on the impact of medical progress in heterogeneous populations
- Role of medical progress and health care spending within declining economies (climate change!)
Thank you!

Happy Birthday DHE!!!